 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Carol Sartorius and Peter Kabos.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.287 |
|
|
|
-
Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32.
Score: 0.425
-
Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2011 Jul; 128(1):45-55.
Score: 0.370
-
McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Mol Cancer Res. 2022 09 02; 20(9):1443-1455.
Score: 0.214
-
Ward AV, Matthews SB, Fettig LM, Riley D, Finlay-Schultz J, Paul KV, Jackman M, Kabos P, MacLean PS, Sartorius CA. Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism. Cancers (Basel). 2022 Mar 31; 14(7).
Score: 0.208
-
Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 03; 61(3):359-371.
Score: 0.203
-
Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 10; 59(10):1129-1139.
Score: 0.186
-
Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 06 23; 22(1):68.
Score: 0.184
-
Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 02 27; 5(4).
Score: 0.180
-
McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ?-catenin dynamics in breast cancer cells. Oncogene. 2020 03; 39(12):2478-2492.
Score: 0.179
-
Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 09 15; 77(18):4934-4946.
Score: 0.150
-
Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 01; 23(7):1710-1721.
Score: 0.142
-
Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2016 06 02; 35(22):2881-92.
Score: 0.132
-
Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul; 34(28):3676-87.
Score: 0.123
-
Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb; 4(1):36-49.
Score: 0.109
-
Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5774-9.
Score: 0.079
-
Rao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Kabos P, Ramachandran S. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Sci Adv. 2022 08 26; 8(34):eabm4358.
Score: 0.053
-
Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer. Br J Cancer. 2021 01; 124(1):217-227.
Score: 0.047
-
Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2019 02 28; 47(4):e20.
Score: 0.042
-
Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14).
Score: 0.040
-
Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017; 7:94.
Score: 0.037
-
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 12; 35(4):547-573.
Score: 0.036
-
Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun. 2015 Dec 21; 6:10077.
Score: 0.034
-
Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May; 14(5):1117-29.
Score: 0.032
-
Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV. Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery. Curr Chem Genom Transl Med. 2014; 8(Suppl 1):27-35.
Score: 0.030
-
Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100.
Score: 0.026
-
Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen. 2012 Oct; 17(9):1211-20.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|